Drugs / cloxacillin
cloxacillin
also known as
BRL-1621 · Cloxacilina · Cloxacillin (as sodium) · CLOXACILLIN SODIUM · Cloxacillin sodium hydrate · Cloxacillin sodium salt monohydrate · Cloxacilline · Cloxapen · +8 more
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | CLOXACILLIN SODIUM | — | 1971-04-01 | fda.gov ↗ |
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00857480 | Jun → Aug 2006 | cirrhosis of liver | Norgine | Completed | No outcome recorded |
| Phase 34 trials · 1 met primary · 1 missed | ||||||
| Phase 3 | NCT07575009 | Apr 2026 → Dec 2028 expected | infectious disease | Tampere University Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT02365493 | Aug 2015 → Oct 2018 | methicillin-resistant staphylococcus aureus infectious disease | Menzies School of Health Research | Terminated | Missed primary |
| Phase 3 | NCT01792804 | Dec 2013 → Mar 2020 | staphylococcus aureus infection | Heinrich-Heine University, Duesseldorf | Completed | Met primary |
| Phase 3 | NCT01875263 | May 2013 → Nov 2014 | staphylococcal infection | Fundación Pública Andaluza Progreso y Salud | Terminated | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT03246360 | Nov 2017 | methicillin-susceptible staphylococcus aureus infectious disease | Centre Hospitalier Universitaire de Nice | Completed | No outcome recorded |
| — | NCT00885300 | Jan → Jul 2008 | — | Shiraz University of Medical Sciences | Completed | No outcome recorded |
| — | NCT00129688 | Apr 2002 → Jun 2004 | cancer, neutropenia | Khon Kaen University | Completed | No outcome recorded |
| Comparator or background therapy17 trials | ||||||
| Phase 0 | NCT02099240 Comparator | Mar 2014 → Nov 2018 | osteomyelitis | University of Louisville | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00077675 Comparator | Feb → Sep 2004 | gram-positive bacterial infections | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00062647 Comparator | Aug 2003 → Aug 2006 | gram-positive bacterial infections | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00061633 Comparator | Jun 2003 → Jan 2004 | abscess, cellulitis, gram-positive bacterial infections, ulcer disease | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/3 | NCT00716183 Comparator | Jul 2008 | mastitis | Universidad Complutense de Madrid | Completed | No outcome recorded |
| Phase 3 | NCT06336824 Comparator | Jun 2024 → May 2025 overdue | staphylococcus aureus infection | Clinical Research Centre, Malaysia | Recruiting | No outcome recorded |
| Phase 3 | NCT02208063 Comparator | Dec 2014 → Apr 2018 | bacterial infectious disease | Cumberland Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT01184872 Comparator | Mar 2010 → Mar 2011 | skin infection | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00772447 Comparator | Sep 2008 → Sep 2010 | infectious disease, skin disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT06712641 Comparator | Apr 2026 → Jun 2028 expected | infectious disease with sepsis | University Hospital, Akershus | Recruiting | No outcome recorded |
| Phase 4 | NCT06726395 Comparator | Mar 2025 → Apr 2028 expected | staphylococcus aureus infection | Region Skane | Recruiting | No outcome recorded |
| Phase 4 | NCT04141787 Comparator | Jul 2019 → Jul 2023 | abscess, bacterial arthritis, infectious disorder of the nervous system, osteomyelitis +1 | Vancouver Island Health Authority | Unknown | No outcome recorded |
| Phase 4 | NCT03959345 Background | May 2019 → Feb 2022 | methicillin-susceptible staphylococcus aureus infectious disease | Miquel Pujol | Terminated | Missed primary Stop: Enrollment |
| Phase 4 | NCT01104662 Comparator | Apr 2010 → Jun 2012 | impaired renal function disease, staphylococcus aureus infection | Merck & Co., Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00711802 Comparator | Jul 2008 → Oct 2013 | skin disease caused by bacterial infection | Merck & Co., Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00423982 Comparator | Apr 2006 → Dec 2012 | periprosthetic joint infection, staphylococcal infection | Oslo University Hospital | Unknown | No outcome recorded |
| — | NCT03248063 Comparator | Sep 2018 → Feb 2024 | methicillin-susceptible staphylococcus aureus infectious disease | Assistance Publique - Hôpitaux de Paris | Completed | Met primary |
Evidence & citations 19 cited values
Every value below carries the sentence it was read from. 26 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cloxacillin | “Vancomycin 1 Gram IV (intravenously) every 12 hrs or nafcillin 2 Grams, oxacillin 2 Grams, or (in South Africa) cloxacillin 0.5 - 1 Gram, IV (intravenously) every 6 hrs for up...” NCT00061633 ↗24“Empirical therapy for suspected community-acquired sepsis with gentamicin + narrow spectrum betalactam (either one of penicillin, ampicillin, or cloxacillin)” NCT06712641 ↗ “patients will receive intravenous cloxacillin 2g/4h and fosfomycin 3 g/6h for the duration of 7 days treatment.” NCT03959345 ↗ “Use of amoxicillin, cloxacillin or amoxicillin/clavulanic acid(500-750 mg), orally, every 8-12 h, for 2-3 weeks” NCT00716183 ↗ “The antibiotics used in the study are benzylpenicillin, cloxacillin, piperacillin-tazobactam and vancomycin.” NCT07575009 ↗ “cloxacillin 0.5 - 1 Gram, IV (intravenously) every 6 hrs for up to 14 days.” NCT00077675 ↗ “Pre-treatment and co-treatment with 1 g Cloxacillin t.i.d. for three days” NCT00857480 ↗ “penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin)” NCT01104662 ↗ “Rifampin 300 mg x 3 po and cloxacillin 2 g x 4 iv for two weeks.” NCT00423982 ↗ “Semi-synthetic Penicillin-Cloxacillin” NCT00772447 ↗ “nafcillin, oxacillin, cloxacillin” NCT00711802 ↗ |
| Known as | BRL-1621 | ChEMBL registry synonym — accepted as the source's own label CHEMBL891 ↗ |
| Known as | Cloxacilina | ChEMBL registry synonym — accepted as the source's own label CHEMBL891 ↗ |
| Known as | Cloxacillin (as sodium) | ChEMBL registry synonym — accepted as the source's own label CHEMBL891 ↗ |
| Known as | CLOXACILLIN SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL891 ↗ |
| Known as | Cloxacillin sodium hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL891 ↗ |
| Known as | Cloxacillin sodium salt monohydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL891 ↗ |
| Known as | Cloxacilline | ChEMBL registry synonym — accepted as the source's own label CHEMBL891 ↗ |
| Known as | Cloxapen | ChEMBL registry synonym — accepted as the source's own label CHEMBL891 ↗ |
| Known as | Cloxypen | ChEMBL registry synonym — accepted as the source's own label CHEMBL891 ↗ |
| Known as | Dariclox | ChEMBL registry synonym — accepted as the source's own label CHEMBL891 ↗ |
| Known as | Ekvacillin | ChEMBL registry synonym — accepted as the source's own label CHEMBL891 ↗ |
| Known as | Latocillin | ChEMBL registry synonym — accepted as the source's own label CHEMBL891 ↗ |
| Known as | Methocillin-s | ChEMBL registry synonym — accepted as the source's own label CHEMBL891 ↗ |
| Known as | Orbenin | ChEMBL registry synonym — accepted as the source's own label CHEMBL891 ↗ |
| Known as | Sodium cloxacillin monohydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL891 ↗ |
| Known as | Tegopen | ChEMBL registry synonym — accepted as the source's own label CHEMBL891 ↗ |
| Modality | Other / unclassified | “Beta-lactam antibiotic” NCT00716183 ↗ |
| Route | Intravenous | “cloxacillin 0.5 - 1 Gram, IV (intravenously) every 6 hrs” NCT00061633 ↗ |